Celularity Inc. Enters Material Definitive Agreement

Ticker: CELUW · Form: 8-K · Filed: Jan 27, 2025 · CIK: 1752828

Sentiment: neutral

Topics: material-definitive-agreement, corporate-event

Related Tickers: CELU

TL;DR

Celularity signed a big deal on Jan 24th. Details to follow.

AI Summary

Celularity Inc. entered into a material definitive agreement on January 24, 2025. The company, formerly known as GX Acquisition Corp., is incorporated in Delaware and headquartered in Florham Park, New Jersey.

Why It Matters

This filing indicates a significant new agreement for Celularity Inc., which could impact its business operations and financial standing.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not yet detailed in this initial filing.

Key Players & Entities

FAQ

What type of material definitive agreement did Celularity Inc. enter into?

The filing states that the Item Information is 'Entry into a Material Definitive Agreement' but does not specify the nature of the agreement.

When was the earliest event reported in this filing?

The earliest event reported was on January 24, 2025.

What is Celularity Inc.'s former company name?

Celularity Inc.'s former company name was GX Acquisition Corp.

Where are Celularity Inc.'s principal executive offices located?

Celularity Inc.'s principal executive offices are located at 170 Park Ave, Florham Park, New Jersey, 07932.

What is Celularity Inc.'s Standard Industrial Classification code?

Celularity Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-01-27 09:00:33

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELULARITY INC . Dated: January 27, 2025 By: /s/ Robert J. Hariri Name: Robert J. Hariri, M.D., Ph.D. Title: Chairman and CEO -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing